Risk Factors For The Continuation Of S-1 Adjuvant Chemotherapy For Gastric Cancer Analyzed From The Jcog1104 Phase Iii Trial.

Takanobu Yamada,Takaki Yoshikawa,Junki Mizusawa,Hitoshi Katai,Akinori Takagane, Shinji Okano,Shin Teshima,Hisayuki Matsushita,Masahiro Goto,Jun Hihara,Yoshiyuki Kawashima,Takeshi Omori,Hisashi Shinohara,Yasuhiro Yuasa,Hiroshi Katayama,Haruhiko Fukuda,Narikazu Boku,Masanori Terashima,Takeshi Sano,Mitsuru Sasako

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 2|浏览9

暂无评分

摘要

196Background: The phase III trial (JCOG1104), comparing between 4- (6 months) and 8-course (1 year) of S-1 as the adjuvant chemotherapy for pathological stage II gastric cancer, registered a total...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要